All Stories

  1. Unraveling the Neural Landscape of Mental Disorders using Double Functional Independent Primitives (dFIPs)
  2. Structural white matter abnormalities in Schizophrenia and associations with neurocognitive performance and symptom severity
  3. Spatial Dynamic Subspaces Encode Sex-Specific Schizophrenia Disruptions in Transient Network Overlap and Their Links to Genetic Risk
  4. Disordered Meaning
  5. Neurostructural subgroup in 4291 individuals with schizophrenia identified using the subtype and stage inference algorithm
  6. Multi-modal deep learning from imaging genomic data for schizophrenia classification
  7. Static and Dynamic Cross-Network Functional Connectivity Shows Elevated Entropy in Schizophrenia Patients
  8. Mental Pain: Psychiatry’s Overlooked Vital Sign
  9. Differences in the neural correlates of schizophrenia with positive and negative formal thought disorder in patients with schizophrenia in the ENIGMA dataset
  10. Connectome architecture shapes large-scale cortical alterations in schizophrenia: a worldwide ENIGMA study
  11. Editorial: Be positive about the negative in pharmacology: Neuropharmacology 2022
  12. Identifying canonical and replicable multi‐scale intrinsic connectivity networks in 100k+ resting‐state fMRI datasets
  13. Auditory oddball hypoactivation in schizophrenia
  14. Chromatic fusion: Generative multimodal neuroimaging data fusion provides multi‐informed insights into schizophrenia
  15. Cortical morphology in patients with the deficit and non-deficit syndrome of schizophrenia: a worldwide meta- and mega-analyses
  16. Editorial: Case reports in neuropharmacology 2022
  17. Establishing Core Symptoms of Acute Serotonin Reuptake Inhibitor Withdrawal: Results from an International Survey of Online Peer-Support Communities
  18. For people with cancer and depression, what are the effects of antidepressants?
  19. A method for capturing dynamic spectral coupling in resting fMRI reveals domain-specific patterns in schizophrenia
  20. A method for estimating and characterizing explicitly nonlinear dynamic functional network connectivity in resting-state fMRI data
  21. Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium
  22. Five negative symptom domains are differentially associated with resting state amplitude of low frequency fluctuations in Schizophrenia
  23. Reliability and clinical utility of spatially constrained estimates of intrinsic functional networks from very short fMRI scans
  24. Multi-model order spatially constrained ICA reveals highly replicable group differences and consistent predictive results from resting data: A large N fMRI schizophrenia study
  25. The Effects of Aging on the Brain for People with Schizophrenia Across 26 Countries
  26. Multi-model order spatially constrained ICA reveals highly replicable group differences and consistent predictive results from fMRI data
  27. The trend of disruption in the functional brain network topology of Alzheimer’s disease
  28. Multimodel Order Independent Component Analysis: A Data-Driven Method for Evaluating Brain Functional Network Connectivity Within and Between Multiple Spatial Scales
  29. An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease
  30. Nonlinear functional network connectivity differences in schizophrenia
  31. Explicitly Nonlinear Dynamic Functional Network Connectivity In Resting-State fMRI Data
  32. Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment
  33. Moving beyond the ‘CAP’ of the Iceberg: Intrinsic connectivity networks in fMRI are continuously engaging and overlapping
  34. Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia
  35. Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease
  36. Spatially constrained ICA enables robust detection of schizophrenia from very short resting-state fMRI data
  37. Building Models of Functional Interactions Among Brain Domains that Encode Varying Information Complexity: A Schizophrenia Case Study
  38. Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium
  39. Path analysis: A method to estimate altered pathways in time-varying graphs of neuroimaging data
  40. Multi-spatial-scale dynamic interactions between functional sources reveal sex-specific changes in schizophrenia
  41. Multi-Model Order Spatially Constrained Ica Reveals Highly Replicable Group Differences and Consistent Predictive Results from Resting Data: A Large N Fmri Schizophrenia Study
  42. Direct linkage detection with multimodal IVA fusion reveals markers of age, sex, cognition, and schizophrenia in large neuroimaging studies
  43. ENIGMA + COINSTAC: Improving Findability, Accessibility, Interoperability, and Re-usability
  44. Converting scores between the PANSS and SAPS/SANS beyond the positive/negative dichotomy
  45. Multi-model Order ICA: A Data-driven Method for Evaluating Brain Functional Network Connectivity Within and Between Multiple Spatial Scales
  46. Tau‐Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease
  47. Reward Processing in Novelty Seekers: A Transdiagnostic Psychiatric Imaging Biomarker
  48. A meta‐analysis of deep brain structural shape and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the ENIGMA Consortium
  49. Author Correction: Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease
  50. Correlation between Alzheimer’s disease and type 2 diabetes using non-negative matrix factorization
  51. Nonlinear Functional Network Connectivity in Resting Fmri Data
  52. Moving Beyond the ‘CAP’ of the Iceberg: Intrinsic Connectivity Networks in fMRI are Continuously Engaging and Overlapping
  53. KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer’s disease
  54. Iatrogenic Delirium in Patients on Symptom-Triggered Alcohol Withdrawal Protocol: A Case Series
  55. Four distinct trajectories of tau deposition identified in Alzheimer’s disease
  56. Brain Density Clustering Analysis: A New Approach to Brain Functional Dynamics
  57. Aberrant Dynamic Functional Connectivity of Default Mode Network in Schizophrenia and Links to Symptom Severity
  58. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment
  59. Multiple overlapping dynamic patterns of the visual sensory network in schizophrenia
  60. Multi-Spatial Scale Dynamic Interactions between Functional Sources Reveal Sex-Specific Changes in Schizophrenia
  61. Aberrant Dynamic Functional Connectivity of Default Mode Network in Schizophrenia and Links to Symptom Severity
  62. Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders
  63. Multiple overlapping dynamic patterns of the visual sensory network in schizophrenia
  64. A safety evaluation of aripiprazole in the treatment of schizophrenia
  65. Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration
  66. Time-varying Graphs: A Method to Identify Abnormal Integration and Disconnection in Functional Brain Connectivity with Application to Schizophrenia
  67. Genetic correlations and genome-wide associations of cortical structure in general population samples of 22,824 adults
  68. Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA
  69. Meta-Modal Information Flow: A Method for Capturing Multimodal Modular Disconnectivity in Schizophrenia
  70. Converting scores between the PANSS and SAPS/SANS beyond the positive/negative dichotomy
  71. A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensamble and on multivariate algorithms, to characterize late onset Alzheimer’s disease
  72. Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification
  73. Covarying structural alterations in laterality of the temporal lobe in schizophrenia: A case for source‐based laterality
  74. The genetic architecture of the human cerebral cortex
  75. Weighted average of shared trajectory: A new estimator for dynamic functional connectivity efficiently estimates both rapid and slow changes over time
  76. Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology
  77. Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease
  78. A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data
  79. Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways
  80. Oxytocin Enhances an Amygdala Circuit Associated With Negative Symptoms in Schizophrenia: A Single-Dose, Placebo-Controlled, Crossover, Randomized Control Trial
  81. Multimodal Hippocampal Subfield Grading For Alzheimer’s Disease Classification
  82. Non-coding variability at the APOE locus contributes to the Alzheimer’s risk
  83. Altered Domain Functional Network Connectivity Strength and Randomness in Schizophrenia
  84. Autoconnectivity: A new perspective on human brain function
  85. Characterizing Whole Brain Temporal Variation of Functional Connectivity via Zero and First Order Derivatives of Sliding Window Correlations
  86. Parallel group ICA+ICA: Joint estimation of linked functional network variability and structural covariation with application to schizophrenia
  87. A method for building a genome-connectome bipartite graph model
  88. The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory
  89. Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?
  90. White matter in different regions evolves differently during progression to dementia
  91. Parallel Group ICA + ICA: Joint Estimation of Linked Functional Network Variability and Structural Covariation with Application to Schizophrenia
  92. The spatial chronnectome reveals a dynamic interplay between functional segregation and integration
  93. A blood-based signature of cerebrospinal fluid Aβ1–42 status
  94. Robust Motion Regression of Resting-State Data Using a Convolutional Neural Network Model
  95. Evaluating trajectories of episodic memory in normal cognition and mild cognitive impairment: Results from ADNI
  96. A review of statistical methods in imaging genetics
  97. Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3
  98. Longitudinal Brain Atrophy Rates in Transient Ischemic Attack and Minor Ischemic Stroke Patients and Cognitive Profiles
  99. Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics
  100. Random forest prediction of Alzheimer’s disease using pairwise selection from time series data
  101. Predicting Alzheimer’s disease progression using multi-modal deep learning approach
  102. Translating Alzheimer's disease–associated polymorphisms into functional candidates: a survey of IGAP genes and SNPs
  103. Amyloid beta–positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activity
  104. Association of CSF CD40 levels and synaptic degeneration across the Alzheimer’s disease spectrum
  105. Disease progression timeline estimation for Alzheimer's disease using discriminative event based modeling
  106. Functional signature of conversion of patients with mild cognitive impairment
  107. Medical Image Imputation From Image Collections
  108. QuickNAT: A fully convolutional network for quick and accurate segmentation of neuroanatomy
  109. MAPT rs242557 variant is associated with hippocampus tau uptake on 18F-AV-1451 PET in non-demented elders
  110. Type 2 diabetes mellitus, brain atrophy, and cognitive decline
  111. Dual-Model Radiomic Biomarkers Predict Development of Mild Cognitive Impairment Progression to Alzheimer’s Disease
  112. A δ Homolog for Dementia Case Finding with Replication in the Alzheimer’s Disease Neuroimaging Initiative
  113. Next Generation Sequencing Analysis in Early Onset Dementia Patients
  114. A framework for linking resting-state chronnectome/genome features in schizophrenia: A pilot study
  115. Cortical thickness atrophy in the transentorhinal cortex in mild cognitive impairment
  116. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data
  117. Spatial dynamics within and between brain functional domains: A hierarchical approach to study time‐varying brain function
  118. A concise and persistent feature to study brain resting‐state network dynamics: Findings from the Alzheimer's Disease Neuroimaging Initiative
  119. Fast Multi-Task SCCA Learning with Feature Selection for Multi-Modal Brain Imaging Genetics
  120. Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia
  121. Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium
  122. A positive take on schizophrenia negative symptom scales: Converting scores between the SANS, NSA and SDS
  123. Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease
  124. Accurate risk estimation of β‐amyloid positivity to identify prodromal Alzheimer's disease: Cross‐validation study of practical algorithms
  125. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome
  126. Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers
  127. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference
  128. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
  129. The spatial chronnectome reveals a dynamic interplay between functional segregation and integration
  130. Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer’s disease
  131. Disrupted network cross talk, hippocampal dysfunction and hallucinations in schizophrenia
  132. Salience–Default Mode Functional Network Connectivity Linked to Positive and Negative Symptoms of Schizophrenia
  133. A Novel Method to Estimate Long‐Term Chronological Changes From Fragmented Observations in Disease Progression
  134. Spatial dynamics within and between brain functional domains: A hierarchical approach to study time-varying brain function
  135. Multimodal neuromarkers in schizophrenia via cognition-guided MRI fusion
  136. Polyomavirus BK-Associated Nephropathy After Kidney Transplantation
  137. Communicability disruption in Alzheimer’s disease connectivity networks
  138. Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer’s Disease using structural MR and FDG-PET images
  139. 18F-florbetapir Positron Emission Tomography–determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery
  140. Integrating semi-supervised label propagation and random forests for multi-atlas based hippocampus segmentation
  141. Multiple incomplete views clustering via non-negative matrix factorization with its application in Alzheimer's disease analysis
  142. Predicting progressions of cognitive outcomes via high-order multi-modal multi-task feature learning
  143. Brain multiplexes reveal morphological connectional biomarkers fingerprinting late brain dementia states
  144. Resting-state thalamic dysconnectivity in schizophrenia and relationships with symptoms
  145. Multimodal Fusion With Reference: Searching for Joint Neuromarkers of Working Memory Deficits in Schizophrenia
  146. Longitudinal Functional Brain Mapping in Supernormals
  147. Pattern Discovery in Brain Imaging Genetics via SCCA Modeling with a Generic Non-convex Penalty
  148. Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group
  149. Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer’s Disease via Fusion of Clinical, Imaging and Omic Features
  150. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
  151. Decreased hemispheric connectivity and decreased intra- and inter- hemisphere asymmetry of resting state functional network connectivity in schizophrenia
  152. Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA Schizophrenia consortium
  153. 75. Disrupted Network Cross Talk, Hippocampal Dysfunction, and Hallucinations in Schizophrenia
  154. Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer’s disease
  155. No health without mental health
  156. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology
  157. Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer’s disease
  158. Morphometricity as a measure of the neuroanatomical signature of a trait
  159. Supervised multimodal fusion and its application in searching joint neuromarkers of working memory deficits in schizophrenia
  160. Modality-Dependent Impact of Hallucinations on Low-Frequency Fluctuations in Schizophrenia
  161. Polygenic risk of Alzheimer disease is associated with early- and late-life processes
  162. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis
  163. A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer’s disease
  164. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults
  165. Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts
  166. The impact of PICALM genetic variations on reserve capacity of posterior cingulate in AD continuum
  167. Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology
  168. The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume
  169. Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy
  170. Higher Dimensional Meta-State Analysis Reveals Reduced Resting fMRI Connectivity Dynamism in Schizophrenia Patients
  171. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI
  172. Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies
  173. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia
  174. Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment
  175. Periventricular hyperintensities are associated with elevated cerebral amyloid
  176. A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin
  177. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression
  178. MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials
  179. Trajectories of Neuropsychiatric Symptoms and Cognitive Decline in Mild Cognitive Impairment
  180. The Function Biomedical Informatics Research Network Data Repository
  181. Neuropsychological profile in adult schizophrenia measured with the CMINDS
  182. Suspected non-AD pathology in mild cognitive impairment
  183. Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer’s disease?
  184. Estimating anatomical trajectories with Bayesian mixed-effects modeling
  185. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes
  186. Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment
  187. Development of a diagnostic test based on multiple continuous biomarkers with an imperfect reference test
  188. Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for assessment of mild cognitive impairment in older adults
  189. Erratum: Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium
  190. Applying Automated MR-Based Diagnostic Methods to the Memory Clinic: A Prospective Study
  191. Identification of Conversion from Normal Elderly Cognition to Alzheimer’s Disease using Multimodal Support Vector Machine
  192. Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment
  193. CFH Variants Affect Structural and Functional Brain Changes and Genetic Risk of Alzheimer’s Disease
  194. Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis
  195. Cerebral Microbleeds, CSF p-Tau, and Cognitive Decline: Significance of Anatomic Distribution
  196. Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects
  197. Amyloid-β11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
  198. A FDG-PET Study of Metabolic Networks in Apolipoprotein E ε4 Allele Carriers
  199. Associations between Verbal Learning Slope and Neuroimaging Markers across the Cognitive Aging Spectrum
  200. A computational atlas of the hippocampal formation using ex vivo , ultra-high resolution MRI: Application to adaptive segmentation of in vivo MRI
  201. Regional flux analysis for discovering and quantifying anatomical changes: An application to the brain morphometry in Alzheimer's disease
  202. Memory, executive, and multidomain subtle cognitive impairment
  203. Multidimensional frequency domain analysis of full-volume fMRI reveals significant effects of age, gender, and mental illness on the spatiotemporal organization of resting-state brain activity
  204. Rich club analysis in the Alzheimer's disease connectome reveals a relatively undisturbed structural core network
  205. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium
  206. Common Variants in PLD3 and Correlation to Amyloid-Related Phenotypes in Alzheimer’s Disease
  207. Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer’s Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer’s Disease Neuroimaging Initiative-1 Baseline Cohort
  208. Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE
  209. Relating Intrinsic Low-Frequency BOLD Cortical Oscillations to Cognition in Schizophrenia
  210. Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease
  211. The Role of Vascular Endothelial Growth Factor in Neurodegeneration and Cognitive Decline
  212. Gaussian Mixture Models and Model Selection for [18F] Fluorodeoxyglucose Positron Emission Tomography Classification in Alzheimer’s Disease
  213. Interaction of Cigarette Smoking History WithAPOEGenotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders
  214. Predictive structural dynamic network analysis
  215. Gray matter atrophy in patients with mild cognitive impairment/Alzheimer's disease over the course of developing delusions
  216. Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction
  217. Multimodal manifold-regularized transfer learning for MCI conversion prediction
  218. In children and adolescents with depression, how do tricyclic drugs affect outcomes?
  219. Brain structure and function as mediators of the effects of amyloid on memory
  220. Effects of changing from non-accelerated to accelerated MRI for follow-up in brain atrophy measurement
  221. Common genetic variants influence human subcortical brain structures
  222. Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures
  223. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression
  224. Functional Magnetic Resonance Imaging of Motor Cortex Activation in Schizophrenia
  225. Neural Correlates of Schizophrenia Negative Symptoms: Distinct Subtypes Impact Dissociable Brain Circuits
  226. Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects
  227. Studying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometry
  228. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function
  229. Highly adaptive tests for group differences in brain functional connectivity
  230. Longitudinal Partial Volume Correction in 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Studies of Alzheimer Disease
  231. Quality Assurance in Functional MRI
  232. The future is now: Model-based clinical trial design for Alzheimer's disease
  233. The Assessment of Psychosis
  234. Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders
  235. Impact of autocorrelation on functional connectivity
  236. Informed Consent: How Much Awareness Is There?
  237. Estimating long-term multivariate progression from short-term data
  238. History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress
  239. Subjective Cognitive Complaints Contribute to Misdiagnosis of Mild Cognitive Impairment
  240. Altered effective connectivity patterns of the default mode network in Alzheimer's disease: An fMRI study
  241. Testing for association with multiple traits in generalized estimation equations, with application to neuroimaging data
  242. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals
  243. Urological Complications in Kidney Retransplanted Patients - A Single Centre Experience.
  244. Overrepresentation of Glutamate Signaling in Alzheimer's Disease: Network-Based Pathway Enrichment Using Meta-Analysis of Genome-Wide Association Studies
  245. Automatic ROI Selection in Structural Brain MRI Using SOM 3D Projection
  246. A multi-scanner study of subcortical brain volume abnormalities in schizophrenia
  247. DYNAMICS OF INTRINSIC CONNECTIVITY NETWORKS IN SCHIZOPHRENIA
  248. Poster #M209 THE LONGITUDINAL COURSE OF SCHIZOPHRENIA: A SYSTEMATIC REVIEW
  249. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer’s disease and mild cognitive impairment
  250. Visual Hallucinations Are Associated With Hyperconnectivity Between the Amygdala and Visual Cortex in People With a Diagnosis of Schizophrenia
  251. Schizophrenia miR-137 Locus Risk Genotype Is Associated with Dorsolateral Prefrontal Cortex Hyperactivation
  252. Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
  253. Converting positive and negative symptom scores between PANSS and SAPS/SANS
  254. Dynamic functional connectivity analysis reveals transient states of dysconnectivity in schizophrenia
  255. Brain Imaging Correlates of Anhedonia
  256. Predictive Factors for Natural Pregnancy after Microsurgical Reconstruction in Patients with Primary Epididymal Obstructive Azoospermia
  257. Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer’s Disease
  258. Faculty of 1000 evaluation for Add-on Treatment of Benzoate for Schizophrenia: A Randomized, Double-blind, Placebo-Controlled Trial of d-Amino Acid Oxidase Inhibitor.
  259. Review: Antipsychotic drugs improve symptoms, with different levels of side effects, in schizophrenia
  260. Improved inference in Bayesian segmentation using Monte Carlo sampling: Application to hippocampal subfield volumetry
  261. D2receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder
  262. Mapping the Genetic Variation of Regional Brain Volumes as Explained by All Common SNPs from the ADNI Study
  263. Faculty of 1000 evaluation for A detailed analysis of the effect of repetitive transcranial magnetic stimulation on negative symptoms of schizophrenia: A double-blind trial.
  264. Segmentation of MR images via discriminative dictionary learning and sparse coding: Application to hippocampus labeling
  265. Deformable Templates Guided Discriminative Models for Robust 3D Brain MRI Segmentation
  266. Functional activity maps based on significance measures and Independent Component Analysis
  267. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
  268. Brain Changes in Older Adults at Very Low Risk for Alzheimer's Disease
  269. Standardization of analysis sets for reporting results from ADNI MRI data
  270. Generative FDG-PET and MRI Model of Aging and Disease Progression in Alzheimer's Disease
  271. aBEAT: A Toolbox for Consistent Analysis of Longitudinal Adult Brain MRI
  272. GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease
  273. Semi-Supervised Multimodal Relevance Vector Regression Improves Cognitive Performance Estimation from Imaging and Biological Biomarkers
  274. Predicting AD Conversion: Comparison between Prodromal AD Guidelines and Computer Assisted PredictAD Tool
  275. Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity
  276. Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly
  277. Predicting the location of human perirhinal cortex, Brodmann's area 35, from MRI
  278. Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning
  279. Man Versus Machine: Comparison of Radiologists’ Interpretations and NeuroQuant®Volumetric Analyses of Brain MRIs in Patients With Traumatic Brain Injury
  280. The Receiver Operational Characteristic for Binary Classification with Multiple Indices and Its Application to the Neuroimaging Study of Alzheimer's Disease
  281. Pharmacovigilance and Beyond
  282. Pharmacovigilance in the New Millennium: Challenges, Opportunities and New Directions
  283. Genetic Variants in the Fat and Obesity Associated (FTO) Gene and Risk of Alzheimer's Disease
  284. Analysis of Copy Number Variation in Alzheimer’s Disease in a Cohort of Clinically Characterized and Neuropathologically Verified Individuals
  285. Relationship between baseline brain metabolism measured using [18F]FDG PET and memory and executive function in prodromal and early Alzheimer’s disease
  286. Dysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: relationships with SNPs in ADNI
  287. Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer’s disease
  288. Classification of Structural MRI Images in Alzheimer's Disease from the Perspective of Ill-Posed Problems
  289. Naming impairment in Alzheimer's disease is associated with left anterior temporal lobe atrophy
  290. Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease
  291. Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease
  292. Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden
  293. Structural Brain Alterations before Mild Cognitive Impairment in ADNI: Validation of Volume Loss in a Predefined Antero-Temporal Region
  294. Vascular burden and Alzheimer disease pathologic progression
  295. Genome-wide pathway analysis of memory impairment in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks
  296. Rates of Decline in Alzheimer Disease Decrease with Age
  297. Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease
  298. Review: Lithium is associated with adverse events in patients with mood disorders
  299. Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
  300. Confirmatory factor analysis of the ADNI neuropsychological battery
  301. Apolipoprotein E ɛ2 and Functional Decline in Amnestic Mild Cognitive Impairment and Alzheimer Disease
  302. Multi-source feature learning for joint analysis of incomplete multiple heterogeneous neuroimaging data
  303. Predicting brain activity using a Bayesian spatial model
  304. Cortical signatures of cognition and their relationship to Alzheimer’s disease
  305. Genetic architecture of resilience of executive functioning
  306. Gender Modulates the APOE  4 Effect in Healthy Older Adults: Convergent Evidence from Functional Brain Connectivity and Spinal Fluid Tau Levels
  307. Identifying disease sensitive and quantitative trait-relevant biomarkers from multidimensional heterogeneous imaging genetics data via sparse multimodal multitask learning
  308. Amyloid-β–Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau
  309. Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer’s Disease
  310. A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment
  311. CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer’s pathological cascade
  312. The Alzheimer’s Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI
  313. Faculty of 1000 evaluation for Dermatoglyphic asymmetries and fronto-striatal dysfunction in young adults reporting non-clinical psychosis.
  314. Longitudinal change in neuropsychological performance using latent growth models: a study of mild cognitive impairment
  315. Identification of common variants associated with human hippocampal and intracranial volumes
  316. Predicting missing biomarker data in a longitudinal study of Alzheimer disease
  317. Multivariate Protein Signatures of Pre-Clinical Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Plasma Proteome Dataset
  318. Faculty of 1000 evaluation for Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.
  319. Does feature selection improve classification accuracy? Impact of sample size and feature selection on classification using anatomical magnetic resonance images
  320. Empirical derivation of the reference region for computing diagnostic sensitive 18fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample
  321. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans
  322. Improved Classification of Alzheimer's Disease Data via Removal of Nuisance Variability
  323. Function biomedical informatics research network recommendations for prospective multicenter functional MRI studies
  324. Fast Identification of Biological Pathways Associated with a Quantitative Trait Using Group Lasso with Overlaps
  325. Design and Application of a Generic Clinical Decision Support System for Multiscale Data
  326. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults
  327. Alzheimer disease biomarkers are associated with body mass index
  328. Multi-Method Analysis of MRI Images in Early Diagnostics of Alzheimer's Disease
  329. Predicting MCI outcome with clinically available MRI and CSF biomarkers
  330. Longitudinal Change of Biomarkers in Cognitive Decline
  331. Longitudinal Course of Schizophrenia
  332. Faculty of 1000 evaluation for Effectiveness of switching from antipsychotic polypharmacy to monotherapy.
  333. Identifying Cognitively Healthy Elderly Individuals with Subsequent Memory Decline by Using Automated MR Temporoparietal Volumes
  334. Faculty of 1000 evaluation for A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes.
  335. The Self and Asperger Syndrome
  336. The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression
  337. Course of Schizophrenia: What Has Been Learned from Longitudinal Studies?
  338. Neurocognitive Deficits, Negative Symptoms, and Insight in Schizophrenia
  339. Genome-wide association study of CSF biomarkers A 1-42, t-tau, and p-tau181p in the ADNI cohort
  340. Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach
  341. Voxelwise genome-wide association study (vGWAS)
  342. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort
  343. Challenges and Solutions in Developing New Medications for Schizophrenia
  344. Using New Antipsychotics in Your Clinical Practice
  345. Faculty of 1000 evaluation for Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial.
  346. Bypassing Shame and Conversion Disorder
  347. Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimerʼs disease
  348. Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment
  349. Multi-modal imaging predicts memory performance in normal aging and cognitive decline
  350. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional–executive network function in Alzheimer’s disease
  351. Faculty of 1000 evaluation for Hippocampal plasticity in response to exercise in schizophrenia.
  352. A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T)
  353. A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly
  354. Faculty of 1000 evaluation for Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.
  355. Sex-dependent association of common variants of microcephaly genes with brain structure
  356. Subregional neuroanatomical change as a biomarker for Alzheimer's disease
  357. Faculty of 1000 evaluation for Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia.
  358. P.1.e.028 Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients
  359. Faculty of 1000 evaluation for Familiality of novel factorial dimensions of schizophrenia.
  360. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
  361. Faculty of 1000 evaluation for Structural neuroimaging in psychosis: a systematic review and economic evaluation.
  362. Tuning in to the Voices: A Multisite fMRI Study of Auditory Hallucinations
  363. Working memory and DLPFC inefficiency in schizophrenia: The FBIRN study
  364. P03-240 Bypassing shame and conversion disorder
  365. Episodic memory loss is related to hippocampal-mediated  -amyloid deposition in elderly subjects
  366. Faculty of 1000 evaluation for Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.
  367. Faculty of 1000 evaluation for Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia.
  368. Magnetic Resonance Imaging of Liver Lesions: Exceptions and Atypical Lesions
  369. Shared Decision Making in Schizophrenia Treatment
  370. Sponsored Clinical Trials and Bias
  371. Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population
  372. TC3A EXCESSIVE TOP-DOWN PERCEPTUAL PROCESSING AND REDUCED REAL-WORLD INVESTMENT EXHIBITED BY PRODROMAL PATIENTS PREDICT SUBSEQUENT CONVERSION TO SCHIZOPHRENIA
  373. Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis
  374. Do Schizophrenia Patients Want to Be Involved in Their Treatment?
  375. Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis
  376. Do Schizophrenia Patients Want to Be Involved in Their Treatment?
  377. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis
  378. Plasma catecholamine metabolites in antidepressant-exacerbated mania and psychosis
  379. Treatment Histories of Patients With a Syndrome Putatively Prodromal to Schizophrenia
  380. MRI Monitoring of Tumor Response to a Novel VEGF Tyrosine Kinase Inhibitor in an Experimental Breast Cancer Model
  381. Antidepressant-Associated Mania and Psychosis Resulting in Psychiatric Admissions
  382. Lamotrigine as Prophylaxis Against Steroid-Induced Mania
  383. PREMATURE POLYPSYCHOPHARMACOLOGY